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Abstract
Objectives. To screen for significant arrhythmias with an implantable loop recorder (ILR) in patients with SSc and no
known cardiovascular disease, and identify associated disease phenotype, blood and cardiovascular magnetic reson-
ance (CMR) biomarkers.
Methods. Twenty patients with SSc with no history of primary SSc heart disease, traditional cardiovascular disease,
diabetes or maximum one traditional cardiovascular risk factor underwent clinical assessment, contrast-enhanced CMR
and ILR insertion.
Results. ILR data were available for 19 patients: 63% female, mean (S.D.) age of 53 (12) years, 32% diffuse SSc. Eight
patients had significant arrhythmias over 3 years: one complete heart block, two non-sustained ventricular tachycardia
[all three dcSSc, two anti-topoisomerase antibodies (Scl70) positive, three interstitial lung disease and two previous
digital ulceration] and five atrial arrhythmias of which four were with limited SSc. These required interventions with one
permanent pacemaker implantation, four anti-arrhythmic pharmacotherapy, one anticoagulation.
Patients with significant arrhythmia had higher baseline high-sensitivity troponin I and N-terminal pro-brain natriuretic
peptide [mean difference (95% CI) 117 (11, 245) and 92 (30, 215) ng/l, respectively], and CMR-extracellular volume
[mean (S.D.) 32 (2) vs 29 (4)%]. Late gadolinium enhancement was observed in five patients, only one with significant
arrhythmia.
Conclusion. This first ILR study identified potentially life-threatening arrhythmias in asymptomatic SSc patients attrib-
utable to a primary SSc heart disease. Disease phenotype, CMR-extracellular volume (indicating diffuse fibrosis) and
cardiac biomarkers may identify at-risk patients that would benefit from ILR screening. Future studies can inform a risk
model and provide insights into SSc-associated arrhythmia pathogenesis.
Key words: SSc, SSc-heart disease, implantable loop recorder detected-arrhythmias, cardiovascular magnetic
resonance (CMR), cardiovascular biomarkers
Rheumatology key messages
. This first implantable loop recorder (ILR) study identified incidental significant arrhythmias in asymptomatic SSc
patients.
. Severe arrhythmias were detected in SSc patients with poor prognostic factors.
. Cardiovascular biomarkers and cardiovascular magnetic resonance-diffuse fibrosis may be useful for screening
significant arrhythmia.
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Introduction
Scleroderma heart disease (SHD) is associated with sig-
nificant mortality, particularly from arrhythmias [1]. The
underlying pathophysiology is distinct from atheroscler-
osis, with autopsy and cardiac magnetic resonance
(CMR) studies demonstrating pathology in areas of the
myocardium unrelated to coronary artery blood flow com-
promise [2, 3]. The hallmark of SHD is myocardial fibrosis,
with or without myocardial inflammation [4], which may
occur independently, or as a consequence of microvascu-
lar-perfusion abnormalities [5]. The pathophysiology of
SHD-associated arrhythmias remains unclear, with fibro-
sis sparing the conduction pathway on autopsy studies,
and not all patients with fibrosis developing clinically rele-
vant arrhythmias [5, 6]. However, conduction abnormal-
ities are more frequent in individuals with ischaemic heart
disease (IHD), with fibrosis the principle underlying patho-
physiological process of sudden cardiac death [7].
Most studies investigating SHD [8, 9] have not at-
tempted to distinguish IHD from primary SHD. Standard
electrophysiological (EP) monitoring methods only cover a
limited period, and such studies have usually reported
supraventricular and ventricular ectopics, which unless
of high burden, are considered benign [9, 10]. The implan-
table loop recorder (ILR) used in the investigation of un-
explained syncope, can record EP data for up to 3 years.
The value of ILR to screen for significant arrhythmias in
asymptomatic but high-risk SSc patients has not yet been
evaluated. CMR imaging provides functional assessment,
but also tissue characterization including detection of
focal and diffuse fibrosis [4, 8] [through late gadolinium
enhancement (LGE) and extracellular volume (ECV) quan-
tification, respectively], and also microperfusion. The as-
sociation between CMR findings and conduction
abnormalities in SSc is not clear.
The primary objective of this electrophysiology and car-
diac imaging in sclerodermA (ELCASA) study was to
assess for significant primary SHD-related cardiac con-
duction abnormalities with the novel use of the ILR, and
to identify disease phenotype, blood and CMR biomarkers
that associate with significant arrhythmias.
Methods
Consecutive patients attending the specialist SSc clinic at
the Leeds Teaching Hospitals NHS Trust were ap-
proached to enter this single centre 144-week-long pro-
spective pilot study. Participants underwent a clinical
evaluation and contrast-enhanced CMR followed by the
insertion of an ILR. Participants were reviewed 3-monthly
for 3 years. All patients gave their written informed con-
sent to take part in the study with approval of the National
Research Ethics Service (12/YH/0298). The study was
conducted according to the Declaration of Helsinki.
Patients
All patients fulfilled the 2013 American College of
Rheumatology/European League of Rheumatism criteria
for SSc [11]. Participants were excluded if they had a
prior diagnosis of primary SHD, traditional cardiovascular
disease, diabetes or more than one traditional cardiovas-
cular (CV) risk factor (defined as current smoker, hyper-
tension, hypercholesterolaemia/hypertriglyceridaemia and
family history of premature CV disease).
Clinical and serum sample collection
Demographic and clinical data, including traditional CV
risk factors were recorded. Fasting lipid profile and glu-
cose, creatine kinase, high-sensitivity cardiac troponin I
(hs-TnI) and N-terminal pro-brain natriuretic peptide (NT-
proBNP) were measured (see Supplementary Methods,
available at Rheumatology online).
CMR protocol
The CMR study was performed on a 3 T Philips Achieva MR
system (Best, The Netherlands). The CMR protocol included
LGE and T1 mapping for ECV quantification (to assess focal
and diffuse fibrosis, respectively), myocardial perfusion,
resting wall motion and left ventricular (LV) function, tissue
tagging and aortic distensibility see Supplementary
Methods, available at Rheumatology online).
ILR
The ILR (Medtronic Reveal XT, Dublin, Ireland) was im-
planted subcutaneously in a left pectoral position. The
device was interrogated every 3 months for 3 years and
if/when the patient was symptomatic.
Statistical analysis
As this was a first pilot study no formal power calculation
was indicated.
The primary outcome was development of significant
arrhythmia (defined as requiring a change in pharmaco-
therapy and/or insertion of anti-arrhythmic device). SPSS
Statistics version 22 (IBM Corp., Armonk, NY, USA) was
used for analysis. Descriptive analyses were undertaken,
including an independent t-test for differences in those
with and without significant arrhythmias. Spearman’s
test evaluated correlations between significant arrhyth-
mias and CV biomarkers and continuous CMR measures.
Results
Twenty patients were recruited, of which 19 had ILR in-
serted and 15 of the 19 had CMR performed
(Supplementary Fig. S1, available at Rheumatology
online); of these 15 with a CMR, LGE and ECV data
could be obtained from 14, and perfusion data from 12.
Baseline characteristics
Eleven patients (63%) were female, mean (S.D.) age of 53
(12) years, and median (interquartile range; IQR) disease
duration of 7.5 (1.8, 19.5) years. Seven patients had
dcSSc and eight had interstitial lung disease. No patient
had a history of pulmonary hypertension. Six and five pa-
tients were ACA and anti-topoisomerase (Scl70) positive,
respectively (Table 1 and Supplementary Table S1, avail-
able at Rheumatology online).
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ILR findings
Over 3 years, the ILR detected findings in 13 (68%) par-
ticipants, from benign to serious arrhythmias
(Supplementary Table S2, available at Rheumatology
online). Eight (42%) patients had significant arrhythmias:
one had complete heart block (CHB); two had non-sus-
tained ventricular tachycardia (NSVT); and five had atrial
arrhythmias of which one had atrial flutter, one had atrial
fibrillation (AF), one had supraventricular tachycardia
(SVT) followed by AF, one had SVT, and one had atrial
flutter followed by AF and SVT. Only one patient reported
palpitations at the time of the arrhythmia (NSVT). The
median (IQR) time from ILR implantation to significant ar-
rhythmia was 12 (4.5, 24) months.
TABLE 1 Disease-specific characteristics of patients with SSc
Characteristic SSc patients (n=19)
Female, n (%) 12 (63)
Presence of RP, n (%) 19 (100)
Time since onset of RP, median (IQR), years 10.1 (2.4, 21.8)
Time since onset of first non-RP symptom, median (IQR), years 7.5 (1.8, 19.5)
History of, n (%)
Digital ulceration 6 (32)
GORD 17 (90)
ILD 8 (42)
Palpitations 9 (47)
Standard of care tested cardio-pulmonary profile, mean (S.D.), %
Forced vital capacity 92 (25)
Total lung capacity 92 (20)
DLCO 63 (16)
DLCO/VA 78 (17)
Electrocardiogram, n (%)
Rhythm 19 (100) sinus rhythm
Axis 2 (11) LAD
Block 1 (5) incomplete RBBB, 1 (5) LBBB,
1 (5) left anterior fascicular block
LV ejection fraction % on echocardiogram, mean (S.D.) 56 (9)
RVRA gradient on echocardiogram, mean (S.D.), mmHga 22 (6) (n= 12)
CV risk profile
Smoking status: never/ex/current, n (%) 8 (42)/11 (58)/0 (0)
Hypertension, n (%) 0 (0)
Hypercholesterolaemia, n (%) 0 (0)
FH premature CVDb, n (%) 2 (11)
Serology and acute phase, n (%)
ANA positive 18 (95)
ACA positive 6 (32)
Scl70 positive 5 (26)
CRP (normal range <5), median (IQR), mg/l 0 (0.0, 1.3)
Cardiovascular biomarkers and lipid profile
hs-TnI, mean (S.D.), ng/l 76 (137)
NT-proBNP, mean (S.D.), ng/l 145 (130)
CK, mean (S.D.), IU/l 141 (148)
Glucose, mean (S.D.), mmol/l 4.8 (0.5)
Total cholesterol, mean (S.D.), mmol/l 4.9 (1.0)
HDL-C, mean (S.D.), mmol/l 1.5 (0.4)
LDL-C, mean (S.D.), mmol/l 2.8 (0.8)
TC/HDL-C ratio, mean (S.D.) 3.7 (1.3)
Triglycerides, mean (S.D.), mmol/l 1.6 (0.8)
aMany values missing due to poor tricuspid regurgitation/image quality. bDefined as first degree relative with a history of CVD
when 60 years old or younger if female, and 55 years old or younger if male. CK: creatine kinase; CV: cardiovascular; CVD:
cardiovascular disease; DLCO: diffusing capacity of the lungs for carbon monoxide; DLCO/VA: DLCO adjusted for volume;
GORD: gastro-oesophageal reflux disease; FH: family history of; HDL-C: high density lipoprotein cholesterol; hs-TnI: high-
sensitivity troponin I; ILD: interstitial lung disease; IQR: interquartile range; LAD: left axis deviation; LBBB: left bundle branch
block; LDL-C: low density lipoprotein cholesterol; LV: left ventricular; NT-proBNP: N-terminal pro-brain natriuretic peptide;
RBBB: right bundle branch block; RP: Raynaud’s phenomenon; RV-RA: right ventricular-right atrial; Scl70: anti-topoisomerase
antibody.
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Of the eight SSc patients with significant arrhythmias, six
were female, with mean (S.D.) age 55 (10) years and median
(IQR) time from first non-Raynaud’s phenomenon symptom
3.1 (20.1) years. All three patients with serious arrhythmias
(NSVT/CHB) were dcSSc with interstitial lung disease,
mean (S.D.) disease duration of 2 (1) years, two of them
males with DU and also Scl70 positive. The other five pa-
tients with atrial arrhythmia were all ACA positive except
one, only one was dcSSc, and one had a history of DU
(Supplementary Table S3, available at Rheumatology
online). There were no complications during the ILR im-
plantation. One patient reported discomfort at the site of
insertion and shoulder during the first year. This persisted
post-ILR removal but with no evidence of infection or
complication.
Baseline CV biomarkers and ILR-detected significant
arrhythmias
hs-TnI and NT-proBNP were higher in the eight patients
with significant arrhythmias compared with those without
[mean difference (95% CI) 117 (11, 245) and 92 (30,
215) ng/l, respectively]. There was no difference in creat-
ine kinase levels between the two groups (Table 2,
Supplementary Fig. S2, available at Rheumatology online).
CMR and development of ILR-detected significant
arrhythmias
CMR-ECV, indicative of diffuse fibrosis, was higher in
those with significant arrhythmias compared with those
without [mean difference (95% CI) 2 (2, 6)%]. Although
within normal range, a trend for greater LV ejection frac-
tion and LV mass appeared in those with significant ar-
rhythmias [mean difference (95% CI) 2 (3, 8)% and 2
(10, 15) g/m2, respectively] (Table 2, Supplementary
Table S4, available at Rheumatology online).
Five of the 14 patients with contrast-enhanced CMR
imaging had evidence of focal fibrosis as evidenced by
LGE; only 1/5 developed a significant arrhythmia (NSVT)
with LGE present in the basal inferolateral midwall. Of the
remaining four, one had transmural LGE in the basal infer-
olateral wall (ILR data available for year 1 only), two had
LGE that was focal in nature and one had LGE that was
diffuse in nature.
None of the 12 patients with perfusion CMR had visual
perfusion defects. Quantitative assessment showed no
differences in myocardial blood flow at rest or stress or
myocardial perfusion reserve between those with and
those without significant arrhythmias.
Baseline CV biomarkers and CMR
CMR-detected fibrosis in itself signifies SHD, albeit subclin-
ical and with unclear clinical implication. Baseline hs-TnI
and NT-proBNP were higher in patients with LGE [mean
difference (95% CI) 91 (14, 196) and 95 (49, 239) ng/l,
respectively] and negatively correlated with myocardial
perfusion reserve (r=0.59, P= 0.053 and r=0.74,
P= 0.006, respectively). There was a trend towards a posi-
tive correlation between hs-TnI and ECV (r= 0.45,
P= 0.125) and negative correlation between hs-TnI and
LV ejection fraction (r=0.39, P= 0.162) (Supplementary
Table S5, available at Rheumatology online).
Medical outcomes for participants
Six participants required medical treatment as a direct
result of the study. The patient with CHB was immediately
admitted for insertion of a permanent pacemaker. Beta-
blockers were commenced for the patients with NSVT and
atrial flutter followed by AF and SVT, with appropriate
monitoring, and calcium channel blocker for the patient
with SVT and AF. Anticoagulation was commenced in
one patient with AF.
TABLE 2 Cardiac serum biomarker and CMR measures in study participants with significant arrhythmias compared with
those without significant arrhythmias
Significant arrhythmia
on ILR (n=8)
No significant arrhythmia
on ILR (n=11)
Mean difference
(95% CI)
Cardiac serum biomarkers
hs-TnI, ng/l 141 (184) 23 (51) 117 (11, 245)
NT-proBNP, ng/l 198 (128) 106 (122) 92 (30, 215)
CK, IU/l 152 (162) 133 (145) 19 (138, 176)
CMR (n= 15)
LGE present (n= 5) 1 (7) 4 (29)
LGE not present (n= 9) 4 (29) 5 (36)
ECV (n= 14) 32 (2) 29 (4) 2 (2, 6)
MPR (n= 12) 1.9 (0.4) 2.1 (1.2) 0.2 (1.3, 0.8)
LVEF 62 (4) 59 (5) 2 (3, 8)
LV mass/BSA, g/m2 46 (7) 44 (14) 2 (10, 15)
Mean (S.D.) values are shown unless stated otherwise. 15/19 patients had CMR performed. Of these 15 with a CMR, LGE and
ECV data could be obtained from 14, and perfusion data from 12. BSA: body surface area; CK: creatine kinase; CMR:
cardiovascular magnetic resonance; ECV: extracellular-volume fraction; hs-TnI: high-sensitivity troponin I; ILR: implantable
loop recorder; LGE: late gadolinium enhancement; LV: left ventricular; LVEF: left ventricular ejection fraction; MPR: myocardial
perfusion reserve; NT-proBNP: N-terminal pro-brain natriuretic peptide.
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Concomitant cardio-pulmonary co-morbidity and
medication
Over the study period, no patients were diagnosed with
pulmonary hypertension or ischaemic CV disease.
Cyclophosphamide use in five patients appeared unre-
lated to development of arrhythmia, with one patient de-
veloping NSVT 1 year following cyclophosphamide
treatment and another with SVT before.
Discussion
This is the first study to evaluate the use of ILR for the
screening of incidental primary SHD-associated arrhyth-
mias. Almost half the patients had a clinically significant
arrhythmia, potentially life-threatening in three. ILR ar-
rhythmias appeared to be associated with hs-TnI, NT-
proBNP and CMR measure of diffuse rather than focal
fibrosis; and incidentally, LGE also correlated with hs-
TnI and NT-proBNP.
Patients with SSc may exhibit traditional IHD and/or pri-
mary SHD. Pathways to risk stratify and manage IHD are
well-established. In contrast, optimal detection and man-
agement of primary SHD remains unclear. EP studies
have relied on short period monitoring methods, with
most including benign findings. There are no data on
pre-emptive ILR use in an unselected general population,
although, emerging data in other at-risk groups identify a
significant proportion developing arrhythmias [12]. Our
study excluded IHD, yet still detected significant arrhyth-
mias, indicating underlying primary SHD aetiology.
The significant arrhythmias were detected over the
course of 3 years, highlighting the limited value of short-
term EP methods. Only one patient reported palpitations
at the time of the arrhythmia, suggesting such history is of
limited value. All three patients with more severe arrhyth-
mias (CHB/NSVT) had early dcSSc and interstitial lung
disease, two were Scl70 positive, two were males, reinfor-
cing the association of SHD arrhythmias with SSc poor
prognostic factors [13, 14].
In individuals with IHD, fibrosis is identified as the prin-
cipal underlying pathophysiological process of sudden
cardiac death [7]. Few studies have assessed the associ-
ation between myocardial fibrosis and EP outcomes in
SSc. Two studies of modest size found no association
[6, 15], whereas another study identified abnormal Holter
monitoring with greater burden of myocardial LGE [2]. In
our study only one of the five patients with LGE had sig-
nificant arrhythmia (NSVT). The location and extent of
myocardial LGE are likely of relevance as both have
been associated with arrhythmias and sudden cardiac
death in cardiomyopathies [16, 17]. Quantitative LGE in
our study revealed low scar mass values, possibly ex-
plaining the absence of association between LGE and
arrhythmias.
This study was a first for evaluating association of CMR-
ECV (a sensitive and quantitative measure of fibrosis) with
arrhythmia. Given the strong association of myocardial fi-
brosis in autopsy studies with arrhythmias [5], and in our
study, the association of diffuse (but not LGE focal) fibro-
sis with arrhythmia, burden of fibrosis may be relevant.
Five arrhythmias were supraventricular, occurring in fe-
males, four ACA positive and only one with dcSSc. None
had common CV causes, implying SHD as the underlying
cause. Further study is required to confirm whether there
is an association of lcSSc with atrial arrhythmias, although
detection of atrial fibrosis on CMR is challenging.
Serum CV biomarkers, hs-TnI and NT-proBNP, are sen-
sitive tools in the detection of cardiac pathology in the
general population, and in SSc [18, 19]. To our knowledge,
ours is the first study to associate primary SHD arrhyth-
mias with hs-TnI and NT-proBNP, implicating myocardial
injury. The mechanism of myocardial damage is not clear
but may reflect microvascular myocardial impairment as a
consequence of endothelial dysfunction and subsequent
scarring. Finally, this study also showed an association of
hs-TnI and NT-proBNP with the CMR measures of fibrosis
and myocardial perfusion reserve. Whilst indicating a sub-
clinical cardiomyopathy, these biomarkers may have pre-
dictive utility in the identification of future clinical SHD.
Cyclophosphamide, notably high dose, is associated
with cardiotoxicity [20]; however, of two patients receiving
cyclophosphamide in our study, there was no temporal
association with the development of arrhythmia.
The main limitation of our study is its modest size.
However, this is a first, pilot study in a rare disease that
has demonstrated the feasibility and utility of the ILR in
asymptomatic individuals. A larger study is warranted to
validate the initial findings and establish a risk model to
inform ILR use in clinical practice.
In summary, this ELCASA study demonstrated ILR-de-
tected incidental significant arrhythmias in asymptomatic
patients. Together with known SSc poor prognostic fac-
tors, this study indicates that CMR-ECV and CV bio-
markers could provide a basis for more refined
screening algorithms and pre-emptive ILR insertion in
the at-risk patient. Finally, the study provides valuable in-
sights into SHD pathogenesis, suggesting an association
between arrhythmias and fibrosis.
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